Clinical Trials Browser

Phase 3 × Colorectal Neoplasms × regorafenib × Clear all

Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03829462 2025-11-21

NEXT-REGIRI

Phase 3 Active not recruiting

377 enrolled 30 charts

Gastrointestinal

Colorectal Neoplasms

NCT05064059 2025-09-17

MK-4280A-007

Phase 3 Completed

441 enrolled 24 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07134205 2025-08-21

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Phase 3 Not yet recruiting

252 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05328908 2025-08-13

RELATIVITY-123

Phase 3 Terminated

770 enrolled

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

Phase 3 Completed

673 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02788279 2019-12-11

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Phase 3 Completed

363 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

NCT01853319 2019-04-22

REGARD

Phase 3 Completed

100 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT01939223 2017-10-20

COAST

Phase 3 Terminated

25 enrolled 6 charts

Gastrointestinal

Colorectal Neoplasms

NCT01584830 2016-02-08

CONCUR

Phase 3 Completed

204 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT01103323 2015-06-24

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Phase 3 Completed

760 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT01786538 2013-03-13

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

Phase 3 Withdrawn

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

CodeBreak300

MK-7902-017

NEXT-REGIRI

MK-4280A-007

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

RELATIVITY-123

AIO-KRK-0114

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

REGARD

COAST

CONCUR

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines